These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 21292815

  • 21. A link between the intrarenal renin angiotensin system and hypertension in autosomal dominant polycystic kidney disease.
    Kocyigit I, Yilmaz MI, Unal A, Ozturk F, Eroglu E, Yazici C, Orscelik O, Sipahioglu MH, Tokgoz B, Oymak O.
    Am J Nephrol; 2013; 38(3):218-25. PubMed ID: 23988725
    [Abstract] [Full Text] [Related]

  • 22. Blood pressure response to exercise in unaffected relatives of autosomal dominant polycystic kidney disease patients: an observational study.
    Yenigun EC, Turgut D, Cevher SK, Yucel C, Aypak C, Dede F.
    Int Urol Nephrol; 2023 Sep; 55(9):2313-2319. PubMed ID: 36872421
    [Abstract] [Full Text] [Related]

  • 23. Levels of Endocan, Angiopoietin-2, and Hypoxia-Inducible Factor-1a in Patients with Autosomal Dominant Polycystic Kidney Disease and Different Levels of Renal Function.
    Raptis V, Bakogiannis C, Loutradis C, Boutou AK, Lampropoulou I, Intzevidou E, Sioulis A, Balaskas E, Sarafidis PA.
    Am J Nephrol; 2018 Sep; 47(4):231-238. PubMed ID: 29597186
    [Abstract] [Full Text] [Related]

  • 24. Hyperaldosteronism and cardiovascular risk in patients with autosomal dominant polycystic kidney disease.
    Lai S, Petramala L, Mastroluca D, Petraglia E, Di Gaeta A, Indino E, Panebianco V, Ciccariello M, Shahabadi HH, Galani A, Letizia C, D'Angelo AR.
    Medicine (Baltimore); 2016 Jul; 95(29):e4175. PubMed ID: 27442639
    [Abstract] [Full Text] [Related]

  • 25. Serum Copeptin, NLPR3, and suPAR Levels among Patients with Autosomal-Dominant Polycystic Kidney Disease with and without Impaired Renal Function.
    Raptis V, Loutradis C, Boutou AK, Faitatzidou D, Sioulis A, Ferro CJ, Papagianni A, Sarafidis PA.
    Cardiorenal Med; 2020 Jul; 10(6):440-451. PubMed ID: 33202410
    [Abstract] [Full Text] [Related]

  • 26. Plasma soluble adhesion molecules; intercellular adhesion molecule-1, vascular cell adhesion molecule-1 and E-selectin levels in patients with isolated coronary artery ectasia.
    Turhan H, Erbay AR, Yasar AS, Aksoy Y, Bicer A, Yetkin G, Yetkin E.
    Coron Artery Dis; 2005 Feb; 16(1):45-50. PubMed ID: 15654200
    [Abstract] [Full Text] [Related]

  • 27. Vascular dysfunction in children and young adults with autosomal dominant polycystic kidney disease.
    Nowak KL, Farmer H, Cadnapaphornchai MA, Gitomer B, Chonchol M.
    Nephrol Dial Transplant; 2017 Feb 01; 32(2):342-347. PubMed ID: 28186577
    [Abstract] [Full Text] [Related]

  • 28. Renin-angiotensin system activation: may it increase frequency of obstructive sleep apnea in patients with autosomal dominant polycystic kidney disease?
    Yalin SF, Atahan E, Gundogdu S, Parmaksiz E, Mese M, Trabulus S, Mutlu B, Altiparmak MR.
    Sleep Breath; 2023 Aug 01; 27(4):1359-1363. PubMed ID: 36372815
    [Abstract] [Full Text] [Related]

  • 29. Association of arginine vasopressin surrogate marker urinary copeptin with severity of autosomal dominant polycystic kidney disease (ADPKD).
    Nakajima A, Lu Y, Kawano H, Horie S, Muto S.
    Clin Exp Nephrol; 2015 Dec 01; 19(6):1199-205. PubMed ID: 25715868
    [Abstract] [Full Text] [Related]

  • 30. Elevated asymmetric dimethylarginine is associated with oxidant stress aggravation in patients with early stage autosomal dominant polycystic kidney disease.
    Raptis V, Georgianos PI, Sarafidis PA, Sioulis A, Makedou K, Makedou A, Grekas DM, Kapoulas S.
    Kidney Blood Press Res; 2013 Dec 01; 38(1):72-82. PubMed ID: 24577239
    [Abstract] [Full Text] [Related]

  • 31. Role of endothelin and nitric oxide in the pathogenesis of arterial hypertension in autosomal dominant polycystic kidney disease.
    Merta M, Reiterová J, Rysavá R, Tesar V, Závada J, Jáchymová M, Zima T.
    Physiol Res; 2003 Dec 01; 52(4):433-7. PubMed ID: 12899655
    [Abstract] [Full Text] [Related]

  • 32. Hypertension in autosomal dominant polycystic kidney disease: observational study in 207 patients with a mean follow-up of 107 months.
    De Almeida EA, Prata MM.
    Rev Port Cardiol; 2007 Nov 01; 26(11):1173-82. PubMed ID: 18297839
    [Abstract] [Full Text] [Related]

  • 33. Differences in hormonal and renal vascular responses between normotensive patients with autosomal dominant polycystic kidney disease and unaffected family members.
    Barrett BJ, Foley R, Morgan J, Hefferton D, Parfrey P.
    Kidney Int; 1994 Oct 01; 46(4):1118-23. PubMed ID: 7861706
    [Abstract] [Full Text] [Related]

  • 34. Left ventricular hypertrophy in autosomal dominant polycystic kidney disease.
    Chapman AB, Johnson AM, Rainguet S, Hossack K, Gabow P, Schrier RW.
    J Am Soc Nephrol; 1997 Aug 01; 8(8):1292-7. PubMed ID: 9259356
    [Abstract] [Full Text] [Related]

  • 35. Endothelial dysfunction and increased carotid intima-media thickness in patients with autosomal dominant polycystic kidney disease.
    Kocaman O, Oflaz H, Yekeler E, Dursun M, Erdogan D, Demirel S, Alisir S, Turgut F, Mercanoglu F, Ecder T.
    Am J Kidney Dis; 2004 May 01; 43(5):854-60. PubMed ID: 15112176
    [Abstract] [Full Text] [Related]

  • 36. RAPID-ADPKD (Retrospective epidemiological study of Asia-Pacific patients with rapId Disease progression of Autosomal Dominant Polycystic Kidney Disease): study protocol for a multinational, retrospective cohort study.
    Ryu H, Park HC, Oh YK, Sangadi I, Wong A, Mei C, Ecder T, Wang AY, Kao TW, Huang JW, Rangan GK, Ahn C.
    BMJ Open; 2020 Feb 06; 10(2):e034103. PubMed ID: 32034027
    [Abstract] [Full Text] [Related]

  • 37. Exercise capacity in polycystic kidney disease.
    Reinecke NL, Cunha TM, Heilberg IP, Higa EM, Nishiura JL, Neder JA, Almeida WS, Schor N.
    Am J Kidney Dis; 2014 Aug 06; 64(2):239-46. PubMed ID: 24787761
    [Abstract] [Full Text] [Related]

  • 38. Screening of QTc interval and global autonomic activity in autosomal dominant polycystic kidney disease and atherosclerotic renal artery stenosis hypertensive patients.
    Lai S, Perrotta AM, Bagordo D, Mazzaferro S, Menè P, Gigante A, Tinti F, Galani A, Cianci R.
    Eur Rev Med Pharmacol Sci; 2021 Oct 06; 25(20):6333-6338. PubMed ID: 34730214
    [Abstract] [Full Text] [Related]

  • 39. Fibulin Levels in Autosomal Dominant Polycystic Kidney Disease and Its Relationship to Arterial Stiffness.
    Inci A, Akin O, Ellidag HY, Eren E, Dolu S, Sari F.
    Clin Lab; 2017 Nov 01; 63(11):1869-1874. PubMed ID: 29226648
    [Abstract] [Full Text] [Related]

  • 40. Renal and cardiac effects of antihypertensive treatment with ramipril vs metoprolol in autosomal dominant polycystic kidney disease.
    Zeltner R, Poliak R, Stiasny B, Schmieder RE, Schulze BD.
    Nephrol Dial Transplant; 2008 Feb 01; 23(2):573-9. PubMed ID: 17984104
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.